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Abstract
Inappropriate activation of the Hedgehog (Hh) signaling pathway in skin is critical for the
development of basal cell carcinomas (BCCs). We have investigated the anti-BCC efficacy of
topically-applied CUR61414, an inhibitor of the Hedgehog signal transduction molecule
Smoothened. In mice, topical CUR61414 significantly inhibited skin Hh signaling, blocked the
induction of hair follicle anagen, and shrank existing BCCs. However, we observed no clinical
activity of this formulation in human superficial or nodular BCCs in a phase I clinical study. Our
data highlight some of the challenges of translating preclinical experience into successful human
results for a topical anti-cancer agent.
Introduction
The Hedgehog (Hh) signaling pathway, which is active during embryonic development (1),
is down-regulated in most normal adult tissues. However, aberrant activation of Hh
signaling due to mutations in genes encoding signaling pathway components underlies most,
if not all, human basal cell carcinomas (BCC), whether arising sporadically or in patients
with the heritable basal cell nevus (Gorlin) syndrome (2); (3–6).
BCCs commonly contain mutations that inactivate the Patched 1 (PTCH1) receptor (4) or
constitutively activate the Smoothened (SMO) receptor (7, 8). Both have the same
functional consequence - the uncontrolled activation of the Hh signaling pathway
independent of the ligand. Activation of the Hh pathway in nearly all human BCCs (9); (10)
is indicated by increased expression of Hh target genes such as the transcription factor,
glioma-associated oncogene homolog 1 (GLI1), and PTCH1, thus suggesting that this is a
causal event in tumor initiation. Additional confirmation of the importance of this pathway
in BCC was provided by studies of genetically engineered mice, which showed that BCC-
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tlike lesions arise following the introduction of similar genetic perturbations that
constitutively activate the Hh signaling pathway (11); (12); (13); (14); (7).
This direct link between the observed genetic mutations and the development of BCC
lesions suggests that the development of molecules acting at the level of or downstream of
SMO could effectively treat various types of BCCs. A proof of concept for the treatment of
locally advanced and metastatic BCC has been provided in the clinic with GDC-0449, an
orally available Hh pathway inhibitor acting at the level of SMO (15). However, a topical
non-systemic Hh pathway inhibitor would be preferable for the treatment of localized BCCs
as it could minimize any possible systemic side effects caused by generalized inhibition of
Hedgehog signaling. Current treatments for superficial or nodular BCC include surgical
excision, electrodessication and curettage, cryosurgery, and topical chemotherapies such as
5-fluorouracil and imiquimod. Scarring following surgical interventions and significant local
skin reactions and limited efficacy restrict the use of the existing topical treatments,
particularly in nodular BCC, and indicate the need for a new topical agent that has
acceptable efficacy and is well tolerated.
CUR61414 is a small-molecule member of the aminoproline class of compounds that was
identified in a high throughput screen for inhibitors of the Hh signaling pathway (16).
Williams et al. demonstrated the potential therapeutic effectiveness of CUR61414 in in vitro
murine models by using an embryonic Ptch1+/− skin explant assay in the presence of
recombinant sonic hedgehog or adult Ptch1+/− skin with UV-induced microscopic BCCs.
Like GDC-0449, CUR61414 acts downstream of the defective PTCH1 through antagonism
of SMO (16).
Here we demonstrate that a topical formulation of CUR61414 can down-regulate Gli-1
expression in normal mouse skin in an in vivo depilatory model and can cause significant
tumor regression in a genetically engineered model of BCC. In addition, the safety,
tolerability, and efficacy are reported for a phase I, double-blinded, randomized, placebo-
controlled, multicenter study of CUR61414.
Results
Epidermal and dermal drug deposition and penetration in human skin
We first studied topically applied CUR61414 in an in vitro human abdominal cadaver skin
percutaneous absorption assay. We formulated a cream base containing increasing
concentrations of CUR61414 (1–4% w/w) spiked with tracer levels of 14C-labeled
CUR61414 (1.0 µCi/3.2 mg formulation dose). Following 24-hour exposure, the quantity of
radioactivity in stratum corneum, epidermis, dermis, and receptor fluid samples indicated
that both the epidermal drug deposition and the skin penetration were enhanced by
increasing the CUR61414 concentration from 1% to 4% in the cream formulations (Table
1). Six to eleven percent and two to five percent of the applied does were absorbed in the
epidermis and dermis layers, respectively.
Topical CUR61414 represses Gli-1 expression in normal mouse skin in a depilatory model
To evaluate the ability of topical formulations of CUR61414 to repress Hedgehog
responsive cells found at the base of hair follicles in normal skin (17); (18), we established
and optimized a depilatory mouse model. The hair follicles in 7-week old C57BL/6 mice are
naturally synchronized in the telogen phase of the hair follicle cycle (Muller-Rover S et al.,
2001), and the onset of anagen, a process accompanied by Hh signaling activation, does not
occur until 12 weeks of age. Chemical depilation with potassium thioglycolate (Nair)
disrupts disulfide bonds, thus damaging hair follicles at the deep root sheath (19). This
damage activates Hh signaling and hence induces the telogen hair follicles in 7-week old
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tmice to undergo anagen. The regeneration of hair follicle depends on the reactivation of
follicle growth by the proliferation of the hair follicle stem cells at the onset of anagen
phase, and Hh has been shown to act as an anagen-inducing signal (20); (21). Time course
analysis of Gli1 mRNA levels in skin following hair removal by a combination of shaving
and Nair application was first performed to determine the magnitude and duration of Hh
pathway activation in response to hair follicle damage (Figure 1a). Nair-induced depilation
significantly elevated Gli1 expression by day 4 (data not shown and Figure 1a), and this
increase in Gli1 expression was maintained through day 7.
To determine whether CUR61414 can block Hh pathway activation in this model, we first
applied two doses of cream containing 1–3% CUR61414 (Figure 1b). Two percent
CUR61414 caused maximal repression of Gli1 expression. Furthermore, application of 2%
CUR61414 twice daily over 3 days was more effective than once daily application (7-fold vs
3-fold Gli1 down-regulation) (Figure 1c).
Topical CUR61414 decreases Hh signaling and shrinks murine BCCs
We next tested the in vivo effects of topical CUR61414 on murine BCCs. After treatment
with tamoxifen at 6 weeks of age and exposure to 4Gy of IR at 8 weeks of age, Ptch1+/−
K14-CreER2 p53 fl/fl mice develop multiple visible nodular BCC tumors starting at 5–6
months of age (Epstein lab, manuscript in preparation). These murine BCCs histologically
resemble nodular human BCCs (Figure 2a). Like BCCs in Ptch1+/− p53 wild type mice
(11) the tumors have a high proliferation index as measured by expression of Ki67 and
express basal cell markers - keratins 14 and 17 (Figure 2a) - but not suprabasalar
differentiation markers - keratin 10 (Figure 2a). These BCC tumors responded dramatically
to topically applied CUR61414. While placebo-treated BCCs increased on average by 40%
in size (as measured by tumor diameter) and none shrank during the course of the study, all
CUR61414-treated BCCs decreased by an average of 60% (p<0.0001) (Figure 2b). Two of
10 CUR61414-treated tumors regressed completely, and the others regressed partially
(>50% decrease). Decreased tumor size could be detected within as few as 6 days of
treatment. Tumor size decrease was paralleled by a significant reduction of Gli1 expression
in CUR61414-treated BCCs compared to placebo-treated tumors (p=0.011) (Figure 2c).
Topical application of CUR61414 significantly reduced tumor proliferation as measured by
Ki67 staining (Figure 2a; Figure 2d, p=0.034) but, unlike in the studies of Williams et al.
(16), did not induce significant apoptosis as measured by cleaved-caspase 3 (data not
shown). The lack of apoptosis in our model could be due to the absence of p53, although
HhAntag treatment appears to increase apoptosis in Ptch1+/−p53−/− murine
medulloblastomas (22). CUR61414 also caused tumor necrosis (Figure 2a) and, after 30
days of application, prominent differentiation of tumor cells as indicated by the development
of large, keratin filled cysts (Figure 2a). Cysts developed in most (67%) CUR61414-treated
BCCs compared to 18% in placebo-treated BCCs (Figure 2e, p=0.02), and cysts in both
treatment groups expressed abundant keratins 14 and 17, but little keratin 10 (Figure 2a).
These data suggest that CUR61414 induced cysts may be derived from BCC tumor cells or
from hair follicles (23) and hence possibly indirectly from follicular stem cells (Wang and
Epstein, Cancer Cell, in press). The cells lining the cysts also have low Ki67 staining. Our
data suggest that topical CUR61414 reduces murine BCCs by decreasing tumor proliferation
as measured by Ki67 and/or inducing follicular differentiation. These encouraging
preclinical data prompted initiation of clinical testing.
Clinical experience with CUR61414 in human BCCs
A Phase I, double-blind randomized, placebo-controlled, multicenter study (clinical trial ID
THA3435g) was initiated to evaluate, as the primary objective, the safety and tolerability of
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ta multidose regimen of CUR61414 (0.09%, 0.35%, 1.1% and 3.1%) applied topically to
human superficial or nodular BCCs for up to 28 days (Figure 3a). Between May 2005 and
June 2006, a total of 42 patients were enrolled from seven sites within the United States (34
patients in the dose-escalation and MTD expansion segments of the study - 29 patients were
randomized to active study drug and 5 to placebo; 8 patients in the PD segment – 6
randomized to active drug and 2 to placebo). No serious adverse events (SAEs) were
reported, even at the highest dose tested of 3.1%. Of the adverse events (AEs) reported, the
majority were skin-related and of mild severity, with one case of severe skin erythema in a
subject treated at the highest dose.
A secondary objective was to assess clinical activity as determined by the percent of tumors
with complete clearance (defined by clinical and histopathologic clearance) after 28 days of
CUR61414 treatment compared to placebo. All target tumors were excised at Day 42. None
of the subjects had complete clearance of their target BCC as defined by complete clinical
and histopathologic clearance. However 2 subjects had histopathologic clearance with
CUR61414 - one subject with a nodular BCC treated with 0.35% cream and the other
subject with a superficial BCC treated with 3.1% cream.
We conducted a separate pharmacodynamic study in which we analyzed GLI1 mRNA levels
in nodular BCCs on 8 patients before and after treatment with CUR61414 twice daily for 3.5
days (Figure 3b). This treatment failed to reduce GLI1 expression. Similarly, we found no
significant changes in gene expression of three other Hedgehog transcriptional target genes
(GLI2, PTCH, and PTCH2) further suggesting a lack of Hh-pathway modulation (data not
shown). Consistent with the qPCR results, isotopic GLI1 and PTCH1 in situ hybridization
(ISH) showed no consistent reduction in GLI1 or PTCH1 transcripts following drug
treatment (Supplementary Tables 1 and 2), and both GLI1 and PTCH1 transcript levels
remained high in the superficial regions of the CUR61414-treated BCC tumors - the regions
closer to the site of the topical treatment - and were comparable to the levels detected in the
deeper layer of the biopsies (Figure 3c; Supplementary Tables 1 and 2).
CUR61414 treatment had little or no effect on the proliferation of BCC tumor cells as
judged by Ki-67 staining (Supplementary Table 3). Likewise, IHC for cleaved caspase-3
revealed little or no impact of CUR61414 treatment on tumor cell apoptosis (Supplementary
Table 4). Similar Ki-67 or cleaved caspase-3 level was observed between superficial and
deep portions of tumors with drug treatment.
Discussion
We have found that topical CUR61414 can down-regulate Gli-1 expression in normal mouse
skin in an in vivo depilatory model and can cause significant tumor regression in a
genetically engineered model of BCC.
The development of a mouse depilatory model described here offered a controlled system
where we could synchronize the hair cycle and reliably monitor drug-induced changes in
Gli1 mRNA levels. We used this model to rapidly screen multiple topical formulations of
CUR61414 and to test various dosing regiments with a sufficiently large number of animals
per group for statistical analysis.
We and others have shown amply that Ptch1+/− mice are susceptible to radiation-induced
BCC tumor formation following cesium-137 irradiation (11, 24). Combining Ptch
heterozygosity with keratin 14-specific deletion of p53 accelerates the rate of BCC tumor
formation, avoids the early development of medulloblastomas that occurs in Ptch+/− p53−/
− mice, and allows the generation of multiple visible BCCs that can be treated and
monitored readily. PK analysis of drug concentrations in the plasma collected at the end of
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tthe study showed negligible levels of systemic drug exposure (data not shown), and we
could detect the effect of topical CUR61414 on Gli1 transcript levels and tumor growth
specifically in the drug-treated BCCs but not on untreated BCCs in the same mouse.
Genetically engineered mouse models of cancers offer powerful tools to test the activity of
potential therapeutic agents (25). Nonetheless, the strong anti-SMO and anti-BCC efficacy
of topical CUR61414 in the mice was inconsistent with its lack of efficacy on human
tumors. In contrast to the murine studies, quantitative RT-PCR and isotopic in situ
hybridization analysis of the human BCC lesions before and after drug treatment showed
unchanged GLI1 expression, indicating lack of exposure. Consequently, CUR61414 did not
achieve the secondary clinical activity endpoint of the Phase I study – there was no complete
clinical and histopathologic clearance. This disparity contrasts with the similar anti-BCC
efficacy of oral celecoxib in mice and humans (26) and indicates that differences between
mouse and human in topical efficacy may exceed those of oral agents.
The lack of clinical efficacy and the failure of topical CUR61414 to down-regulate GLI1 in
human BCCs is likely due to differential potency of the drug on human vs mouse SMO and/
or inadequate drug concentrations in the BCCs due to low penetration or rapid clearance.
CUR61414 is 7.5 fold more potent on mouse than human SMO at inhibiting Hh signaling
activation in in vitro Gli-luciferase assays (IC50 of 0.2µM in murine S12 cells vs. IC50 of
1.5µM in human HEPM cells). This difference in potency could provide a simple
explanation for the disparity we observed between mouse and human BCCs. However, when
applied at the highest dose of 3.1%, the estimated effective concentration of CUR61414 at
the target site is 75 times in excess of the IC50, 112µM based on 2% percutaneous
absorption (Table 1). It is therefore likely that CUR61414 absorption in human BCCs is
significantly lower than that in the human abdominal cadaver skin used in the percutanous
absorption.
We have developed other Hh inhibitors that are 10 to 100 fold more potent than CUR61414
as measured by IC50. The significant efficacy of an unrelated Hh pathway inhibitor,
GDC-0449, delivered orally in patients with locally advanced and metastatic BCCs (15),
illustrates the scientific validity of the target. In the future, new models to test human
percutaneous absorption beyond Franz chamber testing will be needed to more effectively
predict the clinical outcome for topically formulated applications.
Materials & Methods
Murine Studies
Depilatory model—Male mice (Charles River Laboratories, Hollister, CA), 7–8 weeks of
age, at which time the hair follicles all are in telogen phase, and 25–30 grams in body
weight, were used in the study following 2 days of acclimation. Only animals that appeared
to be healthy and that were free of obvious abnormalities were used for the study. Mice,
singly housed during study, were shaved on the dorsal shoulder area, a site difficult for the
mouse to lick, and then treated with the depilatory Nair (Church & Dwight Co., Inc.; active
ingredient: potassium thiogycolate), for 4 minutes before washing off to induce the hair
cycle. Four or five days later, vehicle or drug-containing cream was applied to the depilated
areas (~0.5 cm2). During topical application, mice were under anesthesia.
Gene expression analysis by quantitative PCR—Mouse skin and BCC samples
were homogenized with Polytron homogenizer for 30sec -1min at speed 6. Total RNA was
isolated from the homogenates (Rneasy Fibrous Midi Kit, Qiagen). RNA samples were
DNase-treated (Dnase Kit, Invitrogen), and final RNA concentrations were determined at
OD260. 100ng of RNA was used per well in Taqman quantitative qPCR. Relative mRNA
Tang et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2012 May 15.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tlevels were expressed as [2−(test gene Ct value-reference gene Ct value)] × 1000. The relative Gli-1
mRNA levels were calculated based on normalization to the house keeping gene Rpl19.
Ptch1+/− K14CreER p53 fl/fl mice and in vivo efficacy study—We have used
BCC-susceptible, Ptch1+/− K14Cre-ER2 p53 fl/fl mice as a model for testing small
molecule inhibitors of the Hh pathway. These were generated by breeding mice with the
K14-Cre-ER transgene (27) and mice with a floxed p53 allele (28) with Ptch1+/− mice (29).
Mice were treated at 6 weeks of age with 100µg/day of tamoxifen administered
intraperitoneally for three consecutive days and at 8 weeks of age with 4-Gy ionizing
radiation (IR), 160kV, using an X-ray source (RadSource RS2000 irradiator) to induce BCC
formation by 5 months of age. CUR61414 (3.5% wt/wt, formulated in a topical aqueous
base cream) or placebo base cream was applied topically twice daily to BCCs on the dorsal
skin 5 days a week for up to 42 days. A total of 9 mice with 20 tumors (less than 14mm
diameter) were treated. Two mice had multiple BCCs that were distantly spaced and thus
some BCCs were treated with CUR61414 and others on the same mouse with placebo.
Three mice with closely spaced BCCs were treated with CUR61414 only, and four mice
with tumors were treated with placebo only. In summary, 4 mice with 10 tumors (mean size
7.2 mm) were treated with placebo and 5 mice with 10 tumors (mean size 7.0 mm) were
treated with CUR61414. The largest tumor diameter was measured thrice weekly by
calipers. As per IACUC guidelines, mice with tumors exceeding 20mm in diameter were
euthanized.
β-gal staining and Immunohistochemistry—Seven placebo-treated and six
CUR61414-treated BCCs had enough BCC tumor material for immunohistochemistry and
Ki67 analysis. LacZ-encoded bacterial β-galactosidase was detected by incubation of
glutaraldehyde and formalin fixed tissue with X-gal and iron buffer solution using a β-gal
staining set (Roche Applied Science, Indianapolis, IN) for 48 hours. Mouse tissues were
fixed in 10% buffered formalin, embedded in paraffin, and cut into 5micron sections.
Sections were deparaffinized in xylene and rehydrated through down grading alcohol.
Antigen retrieval was carried out in Trilogy solution (Cell Marque, Rocklin, CA) by heating
in a pressure cooker. Sections were blocked with 3% hydrogen peroxide, Avidin Biotin
blocking system, and normal goat serum (Vector laboratories, Burlingame, CA) prior to
incubation with various rabbit anti mouse polyclonal antibodies [K10 (1:500), K14 and K17
(1:2000) (Covance, Princeton state, NJ), caspase-3 (1:800) (Pharmingen, San Diego, CA)
(overnight at 4°C), and Ki67 (1:400) (Thermo Scientific, Waltham, MA) (60 minutes at
room temperature)] and control rabbit immunoglobulin (1:250). Biotinylated goat anti rabbit
(Vector laboratories, Burlingame, CA) was used to detect the primary antibody and was
followed by incubation with the Vectastain ABC kit (Vector laboratories, Burlingame, CA).
Sections were visualized with liquid DAB and substrate chromogen system (Dako,
Carpinteria, CA) and counterstained with hematoxylin.
Statistical analysis—Nonparametric t-tests (Mann-Whitney) were used to compare the
difference in median values of Gli1 mRNA levels and ordinal values of Ki67 staining
(0:none to <25%, 1: 25–50%, 2: 50–74%, 3: >75% positivity), respectively. Chi-square tests
were used to determine the difference in percentage of tumors with large cysts. All P values
reported are two-sided. Graphpad Prism and STATA v10 were used for statistical software.
Human Studies
In vitro human percutaneous absorption study—This study was conducted using
procedures described previously (30). The CUR61414 formulations (prepared by Dow
Pharmaceutical Sciences) were comprised of CUR61414 (1–4% w/w), benzyl alcohol (0–
3% w/w), propylene glycol (10.0% w/w), methylparaben (0.15% w/w), propylparaben
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t(0.05% w/w), emulsifying wax (15.0% w/w), 10% NaOH solution (q.s. pH 6.0), and purified
water (q.s. to 100). Formulations were spiked with tracer levels (1.0 µCi/3.2 mg formulation
dose) of (14C)-labeled CUR61414. Percutaneous absorption was evaluated using
dermatomed human abdominal skin mounted on Bronaugh flow-through diffusion cells
maintained at 32°C. The receptor fluid, PBS containing 0.1% sodium azide and 1.5% Oleth
20, was continuously pumped under the dermis at a flow rate of 1 ml/hr and collected in 6-
hour intervals. A single dose (~5 mg formulation/cm2) was applied to the skin. Following
24-hour exposure, formulation residing on the skin surface was removed by wiping with two
dry cotton swabs. The stratum corneum was removed from the epidermis with a single
cellophane tape-strip and dissolved in 4ml tetrahydrofuran (THF). The remaining epidermis
was then physically separated from the dermis and digested separately in 2N KOH. Quantity
of radioactivity in the wipes, tape-strip, epidermis, dermis, and receptor fluid samples was
determined using liquid scintillation counting techniques. Epidermal and dermal drug
deposition as well as drug penetration were statistically evaluated by performing unpaired
student’s t-tests (significant differences between formulations are defined with a value of p <
0.05).
Clinical study—A Phase I, double-blind randomized, placebo-controlled, multicenter
study (conducted at 7 investigational sites in the United States) was designed to evaluate the
safety and tolerability of a multidose regimen of CUR61414 topically applied to superficial
or nodular BCCs. The study was reviewed and approved at each investigational site by
institutional review boards in accordance with clinical guidelines. Patients with a single or
multiple superficial or nodular BCC(s) who met the inclusion and exclusion criteria
described in Supplemental Materials and Methods were eligible for study participation. All
patients provided informed consent.
A single BCC lesion, confirmed by biopsy during screening (performed by the Principal
Investigator or a sub-investigator who was a board-certified dermatologist), was targeted for
treatment with the study drug (CUR61414 or placebo). Up to three BCCs per patient were
biopsied at screening to select a single target BCC for treatment. The biopsy site of the
targeted BCC was to be adequately healed (up to 14 days) prior to the initiation of treatment.
Other (nontarget) BCCs that may have been present were not treated with the study drug.
All treated lesions were completely excised to clear margins after the treatment and
observation periods. During all study segments, the evaluating physician assessed safety and
the appearance of the BCC lesion and performed general physical examinations of patients.
For the dose-escalation and MTD expansion segments, the BCC was measured and
documented by digital photography at screening and on Days 1, 8, 15, 22, 28, and 42.
Once the MTD was determined, enrollment began for the PD marker segment. A total of 8
subjects with a biopsy-confirmed nodular BCC were randomized in a 3:1 ratio (CUR61414
to placebo) to receive 3.1% CUR61414 topically applied twice daily [i.e., every 12 hours (±
1 hour)] to the target BCC for 3.5 days, with the final (seventh) dose of study drug being
applied the morning of Day 4. In addition to histopathologic confirmation of the BCC during
the screening period, the biopsy sample was also used to determine the pre-treatment level
of GLI1 expression. Treatment of the BCC consisted of topical application of a continuous
thin film of study drug over the entire surface of the target BCC and margins.
Detailed information about the clinical protocol is described in Supplemental Materials and
Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Determination of the effective concentration of topical CUR61414 in a depilatory
mouse model
a. Time course of Gli1 expression in normal skin after depilatory treatment. Thirty mice
were shaved on the back shoulder area and then treated with the hair removal product Nair
for 4 minutes to induce the hair cycle (day 0). Quantitative RT-PCR was performed to
determine Gli-1 expression in the skin samples from mice sacrificed on indicated days (n=6
per time point). The relative Gli1 expression was derived based on normalization to Rpl19.
Error bars designate mean +/− SEM.
b. Mice (n=6 per group), shaved and Nair-treated, were treated 5 days post Nair with vehicle
(2% benzyl alcohol) or 0.1%, 1%, 2%, or 3.5% CUR61414 wt/wt topically applied twice to
the shaved area (16 hours apart) and sacrificed for skin tissues 4 hours after the second
topical application. Gli1 Ct values [measured as in (a)] were ~22–27.
c. Mice (n=6 per group), shaved and Nair-treated, were treated 4 days post Nair with 2%
benzyl alcohol or 2% CUR61414 wt/wt topically applied to the shaved area twice a day (12
hours apart) for 3 days or once a day (24 hours apart) for 3 days. Skin tissues were harvested
12 hours after the sixth topical application or 24 hours after the third topical application and
Gli1 levels measured as in (a). Gli1 Ct values were ~20–26.
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tFigure 2. CUR61414 mouse BCC Data
a. Representative photos of BCC tumors treated with placebo or CUR61414. CUR61414
treatment leads to BCC regression and cysts or residual microscopic BCCs on histology.
Cysts induced by CUR61414 strongly stain for K14 and K17 and have low staining for K10
similar to placebo-treated BCCs. Cells lining cysts also have low Ki67 staining.
b. BCC tumors treated with 3.5% CUR61414 wt/wt (N=10 tumors, 5 mice) vs. placebo
cream (N=10 tumors, 4 mice) twice daily, 5 days per week. Mean and SEM (error bars) are
shown.
c. Reduced Gli1 mRNA levels (normalized to Rpl19) in tumors treated with CUR61414
(N=8) vs. placebo (N=5), Mean and SEM (error bars) are shown, * p=0.011.
d. Reduced Ki67 staining in tumors treated with CUR61414 (N=7) vs. placebo (N=6), *
p=0.034. Ki67 levels were scored from 0 (none) to 3 (high) as detailed in Materials and
Methods.
e. Percentage of tumors with large cysts, 67% of CUR61414 treated tumors (N=7) develop
cysts on histology compared to 0% of placebo treated BCCs (N=6), * p=0.009. A high
number represents more cysts.
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tFigure 3. CUR61414 Clinical Data
a. (i) Three segments were included in this Phase I trial. The first was a dose-escalation
segment, with four dose groups, for a total of 28 subjects (1). It consisted of four periods:
screening (Day -14 to Day -1), treatment (Day 1 to Day 28), observation (Day 29 to Day
42), and follow-up (Day 43 to Day 56). The second segment was a maximum tolerated dose
(MTD) expansion segment, consisting of the same four periods as the dose-escalation (2).
The third was a pharmacodynamic (PD) marker segment consisted of three periods:
screening (Day −14 to Day −1), treatment (Day 1 to Day 4), and follow-up (Day 5 to Day
18) (3). (ii) Segment 1 is a dose-escalation study (A = active; P = placebo; Tx = treatment).
A low dose of 0.09% was chosen as the starting dose, with subsequent escalation to three
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thigher doses in a stepwise manner once all subjects in the dose level had been treated for 4
weeks and preliminary assessment of safety data indicated minimal or no toxicity.
Concentrations in the higher dose levels were approximately three times the prior
concentration, with the highest dose being 3.1%. One subject was randomized to receive
placebo in each dose level. aAll 7 subjects within a dose group completed the treatment
period (4 weeks) prior to escalation to the next dose. For Dose Levels 1–3, if fewer than 2
subjects (i.e., 1 subject or no subjects) of the 6 actively treated subjects met the criteria for a
DLT following assessment of preliminary safety data, then treatment at the next higher dose
was initiated.
b. Summary of the pre-treatment and post-treatment GLI1 levels in the 8 patients enrolled in
the PD marker segment. In an interim analysis, conducted after 8 patients were treated (2
patients randomized to placebo and 6 patients received study drug), the PD marker was
evaluated by quantitative RT-PCR in the BCC lesion twice: prior to treatment and again in
the excised lesion 4–6 hours following the last of seven doses on Day 4. A paired t-test was
used to statistically compare pre- vs post-GLI1 levels within each treatment group (placebo
and 3.1%) and a twosample t-test was used to compare the treatment differences between
treatment groups. The observed “PD response” that was seen in one subject treated with
placebo was likely due to differences in the cellular content of the post-treatment biopsy, as
SMO expression was similarly decreased.
c. Representative images of GLI1 and PTCH1 in situ hybridization on post-treatment BCC
samples from two patients (Pt. 2 and Pt. 3) who received 7 doses of 3.1% CUR61414 topical
application. A total of 11 matched pre- and post-treatment skin biopsies from four of the 8
PD patients (one placebo- and three CUR61414-treated) were found to contain suitable
tumor material for immunohistochemical and in situ hybridization analyses. GLI1 and
PTCH1 levels (brown spots) in the superficial regions of the skin remained high and
comparable to those detected in the deeper areas of the skin.
Tang et al. Page 13
Clin Cancer Res. Author manuscript; available in PMC 2012 May 15.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tN
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
Tang et al. Page 14
T
a
b
l
e
 
1
a
:
 
P
e
r
c
u
t
a
n
e
o
u
s
 
A
b
s
o
r
p
t
i
o
n
 
o
f
 
C
U
R
6
1
4
1
4
 
(
%
 
o
f
 
a
p
p
l
i
e
d
 
d
o
s
e
*
)
C
U
R
6
1
4
1
4
B
e
n
z
y
l
a
l
c
o
h
o
l
S
i
n
g
l
e
T
a
p
e
-
s
t
r
i
p
E
p
i
d
e
r
m
i
s
D
e
r
m
i
s
R
e
c
e
p
t
o
r
D
o
s
e
R
e
c
o
v
e
r
e
d
1
%
0
%
6
.
6
6
±
2
.
9
5
1
1
.
3
5
±
1
.
8
3
4
.
7
3
±
2
.
6
5
2
.
8
9
±
0
.
6
3
1
0
2
.
8
4
±
9
.
1
7
1
%
1
%
4
.
3
9
±
1
.
9
5
8
.
3
8
±
1
.
8
8
7
.
8
5
±
6
.
2
7
2
.
8
3
±
0
.
5
4
9
1
.
2
6
±
4
.
0
1
1
%
2
%
4
.
9
4
±
2
.
2
2
6
.
7
9
±
1
.
2
7
2
.
5
0
±
1
.
4
3
2
.
0
5
±
.
0
.
0
4
1
0
1
.
5
5
±
1
8
.
9
9
1
%
3
%
3
.
6
0
±
0
.
5
2
6
.
6
2
±
1
.
2
6
1
.
6
9
±
0
.
8
8
2
.
9
7
±
1
.
1
6
9
8
.
9
8
±
1
2
.
7
8
2
%
0
%
5
.
1
0
±
0
.
5
0
5
.
5
7
±
1
.
6
1
2
.
5
5
±
1
.
3
3
1
.
9
9
±
0
.
4
1
9
0
.
0
5
±
1
3
.
0
8
2
%
1
%
5
.
9
4
±
1
.
5
3
6
.
2
8
±
3
.
1
8
2
.
7
2
±
1
.
3
7
2
.
2
8
±
0
.
4
1
9
1
.
8
6
±
7
.
3
8
2
%
2
%
6
.
5
5
±
2
.
3
6
7
.
1
1
±
1
.
9
6
2
.
0
3
±
1
.
4
6
1
.
8
9
±
0
.
1
9
8
2
.
8
6
±
5
.
1
8
4
%
0
%
5
.
3
5
±
1
.
0
7
4
.
2
5
±
0
.
6
5
1
.
9
6
±
2
.
6
6
1
.
7
9
±
0
.
2
0
9
1
.
4
4
±
7
.
6
8
4
%
1
%
5
.
0
0
±
0
.
7
3
4
.
9
1
±
1
.
5
4
1
.
8
0
±
0
.
9
0
2
.
0
9
±
0
.
3
0
9
4
.
5
8
±
1
0
.
0
2
4
%
2
%
5
.
2
1
±
2
.
2
4
5
.
6
4
±
2
.
5
7
1
.
7
2
±
1
.
3
5
1
.
9
0
±
0
.
2
0
8
7
.
8
7
±
5
.
5
8
b
:
 
P
e
r
c
u
t
a
n
e
o
u
s
 
A
b
s
o
r
p
t
i
o
n
 
o
f
 
C
U
R
6
1
4
1
4
 
(
m
a
s
s
,
 
µ
g
*
)
C
U
R
6
1
4
1
4
B
e
n
z
y
l
 
a
l
c
o
h
o
l
S
i
n
g
l
e
 
T
a
p
e
-
s
t
r
i
p
E
p
i
d
e
r
m
i
s
D
e
r
m
i
s
R
e
c
e
p
t
o
r
1
%
0
%
2
.
1
3
±
0
.
9
4
3
.
6
3
±
0
.
5
8
1
.
5
1
±
0
.
8
5
0
.
9
2
±
0
.
2
0
1
%
1
%
1
.
6
2
±
0
.
6
1
2
.
7
3
±
0
.
5
7
2
.
0
5
±
1
.
7
0
0
.
9
1
±
.
0
.
1
7
1
%
2
%
1
.
5
8
±
0
.
7
1
2
.
1
7
±
0
.
4
1
0
.
8
0
±
0
.
4
6
0
.
8
2
±
0
.
3
5
1
%
3
%
1
.
1
5
±
0
.
1
7
2
.
1
2
±
0
.
4
0
0
.
5
4
±
0
.
2
8
0
.
9
5
±
0
.
3
7
2
%
0
%
3
.
2
6
±
0
.
3
2
3
.
5
7
±
1
.
0
3
1
.
6
3
±
0
.
8
5
1
.
2
7
±
0
.
2
6
2
%
1
%
3
.
8
0
±
0
.
9
8
4
.
0
2
±
2
.
0
4
1
.
7
4
±
0
.
8
8
1
.
4
6
±
0
.
2
6
2
%
2
%
4
.
1
9
±
1
.
5
1
4
.
5
5
±
1
.
2
5
1
.
3
0
±
0
.
9
3
1
.
2
1
±
0
.
1
2
4
%
0
%
6
.
8
5
±
1
.
3
7
5
.
4
4
±
0
.
8
3
2
.
5
1
±
3
.
4
1
2
.
3
0
±
0
.
2
6
4
%
1
%
6
.
4
0
±
0
.
9
3
6
.
2
8
±
1
.
9
7
2
.
3
0
±
1
.
1
6
2
.
6
8
±
0
.
3
8
4
%
2
%
6
.
6
6
±
2
.
8
7
7
.
2
2
±
3
.
2
9
2
.
2
0
±
1
.
7
3
2
.
4
4
±
0
.
2
6
*
m
e
a
n
±
S
D
Clin Cancer Res. Author manuscript; available in PMC 2012 May 15.